Coronavirus: mainland China set to approve BioNTech vaccine for foreign residents

[Hamartia Antidote]

Coronavirus: mainland China to approve BioNTech vaccine for foreign residents

Germany’s chancellor has announced limited use for the BioNTech shot in mainland China for foreign residents, but he’s hopeful approval can be expanded.

www.scmp.com

Beijing is expected to approve the use of the BioNTech mRNA Covid vaccines for foreign residents on the mainland, according to German Chancellor Olaf Scholz, who led a large business delegation to China.
“I talked to the premier and the president about working more closely together. This would mean allowing BioNTech for expatriates in China and approving it within China. This would only be a first step, but I hope that the circle of those entitled to use it will be enlarged to the point where BioNTech will be available for anyone who wants it in China,” Scholz said in a joint news conference with Chinese Premier Li Keqiang.

BioNTech CEO Uğur Şahin was among Scholz’s business delegation, which also included senior executives from Adidas, Deutsche Bank, Siemens, Volkswagen and BMW, chemicals giants BASF and Wacker Chemie, and pharmaceutical firms Bayer and Merck.

Three years into the pandemic, China has not given any regulatory approval to foreign-made Covid vaccines in the mainland – even though BioNTech struck a collaboration deal with Shanghai Fosun Pharmaceutical in 2020 to supply its mRNA Covid shots in Greater China. The vaccines are now widely used around the world, including Hong Kong, Macau and Taiwan.
Many foreigners on the mainland took the inactivated vaccines developed by Chinese companies, though some were allowed to take BioNTech shots that were available at foreign embassies.

BioNTech has repeatedly said it hoped to have its mRNA vaccines approved for use across China, but the regulatory review process has been stalled for more than a year.
The approval of the vaccines for use by foreigners has sparked hope for regulatory approval of the vaccines, though whether China would allow them to be used for the general public remains uncertain.

It had been widely expected that even if China allowed broader use of the BioNTech vaccines, they would only be used as a booster shot. More than 90 per cent of the population has received two doses, but by mid-October, only about 57 per cent had taken a booster dose.
China was at first sceptical about mRNA vaccines since they had never been used in people before Covid-19.

The mRNA shots have since become widely used around the world, and China has been racing to develop its own version, but progress has been slow.

A home-grown mRNA vaccine called AWcorna, co-developed by Yuxi Walvax, Suzhou Abogen Biosciences and the Academy of Military Sciences, became available on the mainland at the end of last year, but has not yet received regulatory approval.
In September, Indonesia became the first country to approve the vaccine for emergency use. It was the first authorisation for a Chinese vaccine that uses the same hi-tech platform adopted by Pfizer-BioNTech and Moderna.

China has approved several domestically developed vaccines, five derived through other technologies for general use. Four others have been approved for emergency use, including an inhalable version from CanSino.

Despite the high vaccination rate for two doses, Chinese authorities have repeatedly stressed they will hold firm on the controversial zero-Covid policy, reasoning that many elderly were not fully protected by the vaccine and that large numbers of people could die if China eased the strict measures.

Still, the country is under growing pressure to relax its virus control policy as outbreaks flare up around the country and local governments struggle to implement mass testing and quarantine measures for tens of millions of people each day.

Public anger also continues to build over lengthy lockdowns, which in some extreme cases have led to starvation or even deaths because of delayed treatments for other health emergencies.
The extreme measures have also taken a heavy toll on employment and economic activity across the country.
BioNTech agreed in May last year to form a joint venture with drug maker Fosun, and had completed the construction of a plant in Shanghai capable of supplying up to 1 billion Covid-19 vaccine doses a year. Fosun was to contribute funding and facilities while BioNTech would license the expertise. Production at the plant has not yet started.